Barker, K.L. http://orcid.org/0000-0001-9363-0383
,
Newman, M. http://orcid.org/0000-0002-7228-2022
Stallard, N. http://orcid.org/0000-0001-7781-1512
Leal, J. http://orcid.org/0000-0001-7870-6730
Lowe, C.M. http://orcid.org/0000-0002-1924-2267
Javaid, M.K. http://orcid.org/0000-0001-7985-0048
Noufaily, A. http://orcid.org/0000-0001-8522-6591
Hughes, T. http://orcid.org/0000-0001-9211-6905
Smith, D. http://orcid.org/0000-0001-9177-4201
Gandhi, V. http://orcid.org/0000-0002-5866-1579
Cooper, C. http://orcid.org/0000-0003-3510-0709
Lamb, S.E. http://orcid.org/0000-0003-4349-7195
Funding for this research was provided by:
Health Technology Assessment Programme (10.99.01)
Article History
Received: 3 June 2019
Accepted: 14 August 2019
First Online: 12 November 2019
Compliance with ethical standards
: The trial was approved by the UK South Central Research Ethics Committee (REC: 12/SC/0411) and site-specific approvals were obtained.
: Karen Barker, Meredith Newman, Nigel Stallard, Jose Leal, Catherine Minns Lowe, Angela Noufaily, Tamsin Hughes, David Smith, Sarah Lamb, and Varsha Gandhi declare no competing interests.Dr. Javaid reports personal fees from Optasia and personal fees from Zebra Medical Vision, outside the submitted work.Professor Cooper reports personal fees from Alliance for Better Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB.
: The lead author (KLB) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported.